Identification of covariates modulating B-cell repopulation kinetics in subjects receiving rituximab treatment.

Prolonged rituximab dosing intervals may be effective to achieve B-cell depletion and reduce risk of infection in advanced age or patients with impaired kidney function. Co-medication with corticosteroids or azathioprine prolongs B-cell recovery, which may increase therapeutic effects, but also the rate of adverse events.